Learning & research

Group discussion session at Genetics-inspired Therapeutics for PH

Presented at Genetics-inspired Therapeutics for PH by Chris Rhodes, Imperial College London

Presented at Genetics-inspired Therapeutics for PH by Rachel Gurrell, Apollo Therapeutics

Presented at Genetics-inspired Therapeutics for PH by Patrick Andre, Diagonal Therapeutics

Presented at Genetics-inspired Therapeutics for PH by Alex Rothman, The University of Sheffield and Ana-Maria Tanase, Novartis

Presented at Genetics-inspired Therapeutics for PH by Kevin Hart, Pfizer

Presented at Genetics-inspired Therapeutics for PH by Khodr Tello, Justus-Liebig-Universität Gießen

The SPHInX study is the first-ever randomized controlled trial (RCT) seeking to inform an area of equipoise regarding the efficacy of oral anticoagulation as adjunct therapy in systemic sclerosis-related pulmonary arterial hypertension (SSc-PAH).

Presented at Genetics-inspired Therapeutics for PH by Ardeschir Ghofrani, Justus-Liebig-Universität Gießen

In this study, we compared the clinical efficacy and safety of various Yiqi Chinese medicine injections in chronic pulmonary heart disease (CPHD) through pairwise meta-analyses and indirect comparisons within a systematic review.